Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Drug Profile

Canagliflozin - Johnson & Johnson/ Mitsubishi Tanabe Pharma Corporation

Alternative Names: Canagliflozin-hydrate; Canaglu; Invokana; JNJ-28431754; Sulisent; TA-7284

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Daiichi Sankyo Company; Janssen; Johnson & Johnson; Mitsubishi Tanabe Pharma Corporation; Miyazaki University School of Medicine
  • Class Antihyperglycaemics; Glucosides; Small molecules; Thiophenes
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase III Diabetic nephropathies
  • Phase II Heart failure; Obesity; Type 1 diabetes mellitus

Most Recent Events

  • 26 Jun 2018 Launched for Type-2 diabetes mellitus in China (PO) prior to June, 2018 (CFDA registry, June 2018)
  • 22 Jun 2018 Long-term safety data from CANVAS program in Type-2 diabetes mellitus presented at the 78th Annual Scientific Sessions of the American Diabetes Association (ADA-2018)
  • 13 Apr 2018 Efficacy and safety data from CANVAS program in Type-2 diabetes mellitus and Chronic kidney disease released by Janssen Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top